標(biāo)題: Titlebook: Experimental and Applied Immunotherapy; Jeffrey Medin,Daniel Fowler Book 2011 Springer Science+Business Media, LLC 2011 Cancer.Immunothera [打印本頁] 作者: 搖尾乞憐 時(shí)間: 2025-3-21 16:30
書目名稱Experimental and Applied Immunotherapy影響因子(影響力)
書目名稱Experimental and Applied Immunotherapy影響因子(影響力)學(xué)科排名
書目名稱Experimental and Applied Immunotherapy網(wǎng)絡(luò)公開度
書目名稱Experimental and Applied Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Experimental and Applied Immunotherapy被引頻次
書目名稱Experimental and Applied Immunotherapy被引頻次學(xué)科排名
書目名稱Experimental and Applied Immunotherapy年度引用
書目名稱Experimental and Applied Immunotherapy年度引用學(xué)科排名
書目名稱Experimental and Applied Immunotherapy讀者反饋
書目名稱Experimental and Applied Immunotherapy讀者反饋學(xué)科排名
作者: 音樂會(huì) 時(shí)間: 2025-3-21 23:28
Ruth Stanley (Wissenschaftliche Assistentin)h are often otherwise anergized or tolerized. Another approach that has recently come to fore involves the genetic modification of T cells using genes that confer properties such as new antigen specificity, improved homing to tumor sites, or increased resistance to tumor immune evasion. This chapter作者: Dedication 時(shí)間: 2025-3-22 00:50 作者: 創(chuàng)造性 時(shí)間: 2025-3-22 06:50 作者: Postulate 時(shí)間: 2025-3-22 09:39 作者: 不要嚴(yán)酷 時(shí)間: 2025-3-22 15:46 作者: 不要嚴(yán)酷 時(shí)間: 2025-3-22 20:22 作者: immunity 時(shí)間: 2025-3-23 00:48
Die Zerfallskriege Jugoslawiens,ion, the known effects of Treg cells on current immunotherapy approaches will be discussed. A better understanding of how Treg cells hinder antitumor immunity is required to optimize current therapeutic regimens and to make effective cancer immunotherapy a reality for an increased number of patients作者: 移動(dòng) 時(shí)間: 2025-3-23 04:27 作者: chalice 時(shí)間: 2025-3-23 08:23
ccines, mesenchymalstromal cells, negative regulators in cancer immunology and immunotherapy,non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines withconventional therapies, the combin978-1-62703-822-5978-1-60761-980-2作者: 存心 時(shí)間: 2025-3-23 10:33 作者: CLAIM 時(shí)間: 2025-3-23 16:48
B Lymphocytes in Cancer Immunologyh and impair protective T-cell responses. Therefore, methods to eliminate autoreactive B cells, or switch them to a B effector-1 (Be-1) phenotype that amplifies Th1/Tc1-type T-cell responses, which are typically associated with effective antitumor responses, may improve the clinical outcomes of T-ce作者: 辯論 時(shí)間: 2025-3-23 20:23 作者: TOXIN 時(shí)間: 2025-3-23 22:32 作者: 憤世嫉俗者 時(shí)間: 2025-3-24 05:22 作者: uveitis 時(shí)間: 2025-3-24 09:03 作者: sacrum 時(shí)間: 2025-3-24 12:28 作者: perjury 時(shí)間: 2025-3-24 16:17
Cytokine Immunotherapyne milieu, endogenous protection may be reestablished or even enhanced. It is therefore no surprise that cytokine immunotherapy holds great theoretical promise for the treatment of cancer. This theoretical promise has been borne out in a wide variety of preclinical models but unfortunately, clinical作者: 坦白 時(shí)間: 2025-3-24 21:31 作者: Fillet,Filet 時(shí)間: 2025-3-25 03:10
Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapyer of modified T cells over immunotherapies developed to date such as vaccines or cytokines alone is that T cells have the ability to directly traffic to the site of tumor or infection, to multiply at that site, and to persist in a memory state for months to years.作者: 分開 時(shí)間: 2025-3-25 03:51
MedR Schriftenreihe Medizinrecht drug platform beyond the proof-of-concept stage, future success will depend on broadening and potentiating mAb therapy through antigen discovery, antibody engineering, use of mAbs in combination with chemotherapy and radiotherapy, and personalized medicine.作者: adduction 時(shí)間: 2025-3-25 07:30 作者: CHART 時(shí)間: 2025-3-25 15:38
s and the distinct therapeutic strategies Ideal for laboratoImmunotherapy is now recognized as an essential component of treatment for a widevariety of cancers. It is an interdisciplinary field that is critically dependent upon animproved understanding of a vast network of cross-regulatory cellular 作者: Extricate 時(shí)間: 2025-3-25 16:17 作者: Expand 時(shí)間: 2025-3-25 20:39 作者: consolidate 時(shí)間: 2025-3-26 00:41
Counteracting Subversion of MHC Class II Antigen Presentation by Tumorsvaccines. Here, we discuss the variability of MHC II expression by tumor cells and the impact on the immune response. Also, we address how tumor cells or dendritic cells can be modified . to activate circulating tumor-specific T cells in the fight against cancers.作者: biosphere 時(shí)間: 2025-3-26 05:58 作者: libertine 時(shí)間: 2025-3-26 11:56 作者: 飛來飛去真休 時(shí)間: 2025-3-26 14:01 作者: 量被毀壞 時(shí)間: 2025-3-26 20:09 作者: geometrician 時(shí)間: 2025-3-26 21:50
Dendritic Cell-Based Cancer Vaccines: Practical Considerationsions of cell-based immunotherapy. Specific issues include optimization and standardization of cell specific products, identification of ideal patients and cancer subtypes as well as methods to comprehensively evaluate the host response and more fully understand underlying biological effectors that are engaged.作者: Dealing 時(shí)間: 2025-3-27 02:15
Negative Regulators in Cancer Immunology and Immunotherapy and immunotherapy. In this chapter, we describe some of these immunosuppressive mechanisms and components that are linked in complex networks. A better understanding of these mechanisms will eventually lead to improvements of cancer immunotherapies.作者: Spinous-Process 時(shí)間: 2025-3-27 06:46 作者: forager 時(shí)間: 2025-3-27 10:35
Combining Cancer Vaccines with Conventional Therapiesese issues and results from recent experiments demonstrating the combining vaccination with surgical resection or chemotherapy can greatly enhance the activity of cancer vaccines in situations of large tumor burden.作者: expansive 時(shí)間: 2025-3-27 15:39
Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancerections (e.g., cytomegalovirus [CMV], Epstein-Barr virus [EBV], and adenovirus) and virus-associated diseases, such as EBV-associated lymphoproliferative disease (LPD), that arise in the immunocompromised host. This therapeutic approach has also been extended to the treatment of cancer and has shown作者: FER 時(shí)間: 2025-3-27 21:00
B Lymphocytes in Cancer Immunologys with solid tumors harbor circulating antitumor antibodies and most tumors contain a population of infiltrating B cells implying an association between oncogenic events and B-cell activation. B-cell immunity can be beneficial by providing antibody-mediated protection from oncogenic viruses or a sou作者: 逗留 時(shí)間: 2025-3-27 23:30 作者: LIMIT 時(shí)間: 2025-3-28 03:22
Natural Killer Cells for Cancer Immunotherapyatively underrepresented in the medical literature, due in part to the strong emphasis placed on studying the mechanisms of the antigenic specificity and memory of T and B lymphocytes. Fortunately, as innate cells have gained prominence in recent years, NK cell research has blossomed and we now have作者: 厭倦嗎你 時(shí)間: 2025-3-28 07:02 作者: Glutinous 時(shí)間: 2025-3-28 14:05 作者: 不妥協(xié) 時(shí)間: 2025-3-28 16:10
Tumor-Specific Mutations as Targets for Cancer Immunotherapyroteins. When pathogens enter a host, they introduce foreign proteins to which the host is not tolerant, and an immune response ensues. In contrast, tumors represent a special case, as the vast majority of tumor proteins are “self” and hence do not trigger immune activation. However, mutation of gen作者: CODA 時(shí)間: 2025-3-28 21:50
Counteracting Subversion of MHC Class II Antigen Presentation by Tumorsmor growth is well established, we are still looking for ways to harness the MHC class II antigen presentation pathway for the development of an efficient immune response. Learning the mechanisms by which tumors circumvent the immune responses is the first step towards the development of cell-based 作者: BATE 時(shí)間: 2025-3-29 02:05 作者: 變色龍 時(shí)間: 2025-3-29 06:41
T Regulatory Cells and Cancer Immunotherapyuncontrolled inflammatory and auto-immune responses that would otherwise harm self. T regulatory (Treg) cells are central to this process and are required to maintain self-tolerance by actively inhibiting self-reactive T cells by a variety of direct and indirect mechanisms. Numerous studies have sho作者: enmesh 時(shí)間: 2025-3-29 09:11
Negative Regulators in Cancer Immunology and Immunotherapyk side” of tumor immunity is immune evasion. That is, by the time a patient suffers from a clinically-detectable tumor, the tumor has already successfully evaded cancer immunosurveillance and often has established effective mechanisms to actively suppress the immune system, particularly in the tumor作者: 蟄伏 時(shí)間: 2025-3-29 13:01
Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapyeptors (TCRs) or through the antigen-specific antibody-based chimeric antigen receptors (CARs). By either method, the advantage of the adoptive transfer of modified T cells over immunotherapies developed to date such as vaccines or cytokines alone is that T cells have the ability to directly traffic作者: 合群 時(shí)間: 2025-3-29 18:50 作者: Diverticulitis 時(shí)間: 2025-3-29 20:26
Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapyion status of histones affects levels of gene expression, and causes aberrant transcriptional repression in cancer cells. As a result, this is also implicated with unresponsiveness to immune-based therapies as well as conventional chemotherapies against cancer. To sensitize cancer cells to those the作者: 暫時(shí)中止 時(shí)間: 2025-3-30 02:00 作者: Benign 時(shí)間: 2025-3-30 07:16
https://doi.org/10.1007/978-1-60761-980-2Cancer; Immunotherapy; translational immunotherapy作者: Immunotherapy 時(shí)間: 2025-3-30 10:11 作者: Phenothiazines 時(shí)間: 2025-3-30 14:41
Ruth Stanley (Wissenschaftliche Assistentin)ections (e.g., cytomegalovirus [CMV], Epstein-Barr virus [EBV], and adenovirus) and virus-associated diseases, such as EBV-associated lymphoproliferative disease (LPD), that arise in the immunocompromised host. This therapeutic approach has also been extended to the treatment of cancer and has shown作者: Magisterial 時(shí)間: 2025-3-30 16:59
Der traumatische Einbruch des Triebhaften,s with solid tumors harbor circulating antitumor antibodies and most tumors contain a population of infiltrating B cells implying an association between oncogenic events and B-cell activation. B-cell immunity can be beneficial by providing antibody-mediated protection from oncogenic viruses or a sou作者: PALSY 時(shí)間: 2025-3-30 20:45 作者: 小蟲 時(shí)間: 2025-3-31 01:08
Gewalt von Rechts — (k)ein Fernsehthema?atively underrepresented in the medical literature, due in part to the strong emphasis placed on studying the mechanisms of the antigenic specificity and memory of T and B lymphocytes. Fortunately, as innate cells have gained prominence in recent years, NK cell research has blossomed and we now have作者: DEMN 時(shí)間: 2025-3-31 05:45
,Zur Gewaltf?rmigkeit von Kultur,py. The ability to use clinical cell processing to safely and effectively generate novel autologous cell-based therapies has led to a rapid expansion in early phase clinical trials evaluating the potential of cell-based cancer immunotherapies. These studies have demonstrated both feasibility and rem作者: countenance 時(shí)間: 2025-3-31 10:06
https://doi.org/10.1007/978-3-662-47054-1rentiate into several mesenchymal lineages, as well as their role in hematopoiesis, provided the basis for several clinical investigations in the field of regenerative medicine, ranging from heart repair to hematopoietic support in patients undergoing hematopoietic peripheral blood progenitor cells
